Stay updated on Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The study record was updated on November 16, 2026, and the University of Chicago Medical Center location in Chicago changed its status to “Not yet recruiting.” The contact phone number was reformatted without changing its digits.
    Difference
    0.5%
    Check dated 2026-11-18T01:54:03.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The clinical trial record for the ovarian cancer immunotherapy study is now displayed instead of an error page, with details about participation criteria, interventions, locations, and study outcomes.
    Difference
    66%
    Check dated 2026-11-11T01:08:22.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The site footer revision identifier changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 error.
    Difference
    0.2%
    Check dated 2026-11-03T23:21:07.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    An NIH-wide banner about the transition from “Artificial Intelligence” to “Super Intelligence” appeared, and the site revision label changed from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error.
    Difference
    1%
    Check dated 2026-10-20T22:53:45.000Z thumbnail image
  5. Check
    47 days ago
    Change Detected
    Summary
    The site revision in the footer changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-06T23:08:19.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The study page now renders a 403 Forbidden error instead of the study details, effectively blocking access to the IPROC record. The visible content shows a standard 403 layout and message.
    Difference
    20%
    Check dated 2026-09-22T23:10:02.000Z thumbnail image

Stay in the know with updates to Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page.